Galileo Genomics Selects LabVantage Solutions’ LIMS
LabVantage Solutions, Inc. and Galileo Genomics, Inc. announced that Galileo has signed a software and services agreement for LabVantage Sapphire Life Sciences LIMS. Galileo’s initial utilization of Sapphire will address the management information of its microsatellite and SNP genotyping.
It is expected that implementation of Sapphire will allow Galileo to expand its laboratory operations to perform dense genome-wide scans on at least 40 diseases within the next three years, followed by fine mapping of small candidate regions and identification of disease-related sequence variations. This process includes over 3 billion genotypes on DNA samples from approximately 60,000 patients, relatives, and controls, generating terabytes of raw and derived data. LabVantage Sapphire Life Sciences LIMS is an important component of Galileo’s compliance with GCP and GLP regulations (including the support for electronic signatures and compliance with 21 CFR Part 11), and of ensuring the integrity and quality of Galileo’s research data.
“The selection of LabVantage as a preferred technology partner resulted from Sapphire’s ability to closely mirror our LIMS requirements without the need for extensive design, development and customization,” said Dr. John Hooper, President and CEO of Galileo. “We are looking forward to working with the LabVantage team in helping Galileo, its clients, and its partners in other countries, to achieve their goals.”
“We are pleased to have been chosen by Galileo Genomics as a key data and information management solution provider for their genetics research efforts,” said Jim Aurelio, President and CEO, LabVantage Solutions. “The strength of the Sapphire Genetics Industry Solution lies in its robust functionality and ability to rapidly mirror requirements of genetics-focused researchers without complex and overly resource-intensive implementation efforts.”
